The abundance of mAbs that have been granted FDA approval and the number of cancer types for which they are used continues to grow, which is reflective of the enthusiasm for PD-1/PD-L1 inhibition and its potential application in clinical practice [200]. This evidence concerns the gene PDCD1 and cancer.